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Barbara M. Martin, Michael T. McIntosh,1 Tammy R. Beckham
Abstract. Classical swine fever (CSF) is an economically devastating disease of pigs. Instrumental to the control of CSF is a
well-characterized assay that can deliver a rapid, accurate diagnosis prior to the onset of clinical signs. A real-time fluorogenicprobe hydrolysis (TaqMan) reverse transcription polymerase chain reaction (RT-PCR) for CSF was developed by the United
States Department of Agriculture (USDA) at the Plum Island Animal Disease Center (CSF PIADC assay) and evaluated for
analytical and diagnostic sensitivity and specificity. A well-characterized panel including Classical swine fever virus (CSFV),
Bovine viral diarrhea virus (BVDV), and Border disease virus (BDV) isolates was utilized in initial feasibility and optimization
studies. The assay was initially designed and validated for use on the ABI 7900HT using the Qiagen QuantiTect® Probe
RT-PCR chemistry. However, demonstrating equivalency with multiple one-step RT-PCR chemistries and PCR platforms
increased the versatility of the assay. Limit of detection experiments indicated that the Qiagen QuantiTect® Multiplex (NoROX)
and the Invitrogen SuperScript® III RT-PCR kits were consistently the most sensitive one-step chemistries for use with the CSF
PIADC primer/probe set. Analytical sensitivity of the CSF PIADC assay ranged from <1–2.95 log10 TCID50/ml on both the
ABI 7900HT and ABI 7500 platforms. The CSF PIADC assay had 100% diagnostic sensitivity and specificity when tested on
a panel of 152 clinical samples from the Dominican Republic and Colombia. The ability to perform this newly developed assay
in 96-well formats provides an increased level of versatility for use in CSF surveillance programs.
Key words: Blood; classical swine fever; hog cholera; virus; Classical swine fever virus; swine; pigs; RNA; real-time
reverse transcription polymerase chain reaction.
Classical swine fever (CSF) is a highly contagious viral disease of domestic and wild pigs. The etiological agent is the
Classical swine fever virus (CSFV), an enveloped virus
belonging to the genus Pestivirus in the family Flaviviridae.
Other animal pathogens within this genus include Bovine
viral diarrhea virus 1 and 2 (BVDV) and Border disease
virus (BDV), both of which can infect pigs.4 Although
BVDV and BDV do not cause clinical disease in swine, antibodies produced in pigs infected with these agents are
cross-reactive with CSFV antigen, reducing the specificity
of serological-based assays.9
Some of the current diagnostic methods for CSF include
the detection of viral antigens in tonsils using fluorescent conjugated antibody, antigen capture enzyme-linked immunosorbent assays (ELISAs),2 or detection of genomic RNA by
reverse transcription polymerase chain reaction (RT-PCR).5,6,10
The disease may present in a peracute, acute, subacute,
chronic, or persistent form. Subacute and chronic forms of
CSF are often associated with previously vaccinated herds or
low virulence viruses and may remain clinically undetected.9
In this regard, infection with low virulent viruses often do not
present with clinical signs consistent with CSF. As CSF is

classified as a notifiable disease to the World Organization for
Animal Health (OIE) and the economic consequences of an
outbreak are significant, rapid and accurate diagnosis or ruleout of CSF is essential. This is particularly the case, as serological and antigen tests incur a potentially high false-positive
rate due to cross-reactivity occurring with BVDV and BDV.2,4
The objective of the current study was to develop a reliable, sensitive, and specific real-time reverse transcription
polymerase chain reaction (real-time RT-PCR) test for CSF
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Table 1. Development, optimization, and validation of a Classical swine fever virus real-time reverse transcription polymerase chain
reaction assay: primer and probe sequences designed for the detection of viral RNA.*
Name

Designation

Tm

Sequence

Position

PIADC-F
PIADC-R
PIADC-P

Forward
Reverse
Probe†

59
58
69

TGCCCAAGACACACCTTAACC
GGCCTCTGCAGCGCCCTAT
TGATGGGAGTACGACCTG

241–261
314–332
296–313

*PIADC = Plum Island Animal Disease Center; Tm = melting temperature of nucleotide sequence.
†Probes were labeled with 6-carboxyfluorescein (FAM) at the 5′ end and with minor groove-binding nonfluorescent quencher dye (MGBNFQ) at the 3′ end.

and validate it for fitness for use with nasal swabs from
pigs. The new assay, named Classical Swine Fever Plum
Island Animal Disease Center (PIADC CSF) real-time
RT-PCR, was compared with the previously developed
Risatti CSF real-time RT-PCR8 assay deployed for use in
the U.S. CSF Surveillance Program. Experimental observations including assay equivalency, repeatability, and agreement were evaluated and determined using statistical
analyses to compare the PIADC CSF assay to the previously developed Risatti CSF assay.8 Beyond this study is
the additional validation of the PIADC CSF assay on other
clinical sample types, such as whole blood from swine.3
Viral RNA was purified from cell culture propagated
virus and clinical swab samples using a commercial kit.a A
total of 160 sequences spanning all major genotypic groups
and subgroups of CSFV, including 105 CSFV, 28 BVDV,
and 27 BDV strains, were aligned to genotype 1.1 reference
CSFV Alfort 187 using BioEdit software.b This alignment
was used to design a TaqMan probe,c forward and reverse
primersd for the PIADC CSF assay (Table 1). All primers
were synthesized and purified by column purification.d Probe
sequences were synthesized and labeled with 6-carboxyfluorescein (FAM)d at the 5′ end and with minor groove-binding
nonfluorescent quencher dye (MGBNFQ)e at the 3′ end.
Three, one-step RT-PCR kits were tested to optimize the new
assay: the QuantiTect® Probe RT-PCR Kit,f QuantiTect®
Multiplex-NR RT-PCR NoROX Kit,g and SuperScript® III
RT-PCR Kit.h For the PIADC CSF assay, the final reaction
mixture consisted of 22.5 µl of master mix including optimized concentrations of 0.2 µM forward primer, 0.4 µM
reverse primer, and 0.2 µM probe (Table 1), and 2.5 µl of
viral RNA. Additionally, ROXi (2.5 µM) was added to a final
concentration of 50 nM to the Multiplex-NRg and SuperScript
IIIh master mixes for use with the PIADC CSF assay on the
ABI 7500 Fastj platform. Alternately, ROX (25 µM) was
added to a final concentration of 500 nM to the Multiplex-NR
and SuperScript III master mixes for use with the PIADC
CSF assay on the ABI 7900HTk platform.
Cycling conditions on the ABI 7900HT and ABI 7500
were as follows: reverse transcription at 50°C for 30 min,
enzyme activation at 95°C for 15 min, followed by 45 cycles
at 94°C for 15 sec and 56°C for 60 sec. Fluorescence data
for all real-time RT-PCR assays were acquired during the
annealing and extension phase in the reaction using the FAM

detection channel on each instrument. The results were designated positive for threshold cycle (Ct) values <40, and
negative for a Ct values ≥40 or negative for samples with
which threshold had not been attained before cycling completed at 45 cycles. Positive and negative amplification and
extraction controls were included in each evaluation. The
CSF PIADC assay was performed on the ABI 7900HT and
ABI 7500 (in standard mode), and the Risatti CSF assay was
performed on the SmartCycler IIl and ABI 7900HT for
direct comparison of the assays without differences due to
the platform.
Analytical sensitivity and specificity of the CSF PIADC
assay were determined using a panel of 157 CSFV, 6 BVDV,
and 3 BDV isolates, and pestivirus-negative samples. The analytical panel of virus isolates was evaluated using the optimized assay conditions (above) for the CSF PIADC assay
on the ABI 7900HT and ABI 7500 platforms and the Risatti
CSF assay on the SmartCycler II platform (raw data not
shown). Raw data from an additional smaller representative panel of 21 CSFV, 6 BDV, and 5 BVDV isolates is presented (Table 2).
For sensitivity and limit of detection (LOD) studies,
infectious titers of 9 different CSF isolates were determined
by calculating end-point titrations using median tissue culture infectious dose (TCID50; Table 3). Analytical performances and sensitivities of the CSF PIADC assay were
determined by analyzing 10-fold dilutions of purified CSFV
RNA from titered isolates of CSFV using master mixes prepared from the Probe, Multiplex-NR, and SuperScript III
chemistries and amplification on the ABI 7900HT or ABI
7500 platforms (Table 3). Diagnostic sensitivity and specificity were determined by testing 58 known positive nasal
swab samples from the Dominican Republic7 and 93 known
negative nasal swab samples from Colombia7 using the optimized CSF PIADC and Risatti CSF assays.
Using a large panel of 157 CSFV, 6 BVDV, and 3 BDV
isolates, analytical sensitivity was found to be greater than
0.99 (95% confidence interval [CI]: 0.96, 1.00) for both the
CSF PIADC and the Risatti CSF assays. Analytical specificities were 0.92 (95% CI: 0.58, 0.99) and 0.68 (95% CI:
0.40, 0.87) for the CSF PIADC and Risatti CSF assays,
respectively. Both assays resulted in negative reactions for
all BVDV isolates tested; however, the Risatti CSF assay
consistently resulted in the positive detection of BDV.

996

Eberling et al.

Table 2. Development, optimization, and validation of a Classical swine fever virus real-time reverse transcription polymerase chain
reaction assay: comparison of threshold cycle values between assays and platforms used.*
Assay threshold cycle values
Risatti8 CSF

PIADC CSF
Pestivirus isolate
CSFV
V.1081/94 10/12/01
Trem. Cong. 10/19/01
Visbek/Germany 1995
Parma 98
Vi 2837/38/Germany 99
CPA317-3
San Cristobal A tons
Texen 8/98 Edo Mexico
Degen 7/98 Jalisco
Texcoco 98 Mexico
Percen 97 Mexico
Ames Plaque
Guatamala 85053.02
Alfort: 10/19/01
VD Bergen: Aug 97
PAV 250 Vaccine
Costa Rica
Paderborn
DR Bavaro
Brescia
Kanagawa
BDV
Gifhorn
137/4
Chemnitz
Moredun
Aveyron
Frijters
BVDV
NADL
Singer
HVT2
Costa Rica
Rutten

Genotype

3.1

1.2
2.1
1.2
3.4

1
1

Source

ABI 7900HT

SmartCycler II

ABI 7900HT

PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC
PIADC

29.9
21.84
22.89
27.57
23.59
21.29
25.76
33.44
28.86
30.44
24.02
21.45
18.33
21.33
23.63
33.51
27.82
27.75
33.75
19.89
32.22

35.4
25.96
42.95
25.81
30.6
26.92
29.63
NT
42.81
38.3
29.54
NT
20.41
27.99
25.81
UD
29.33
27.09
39.47
26.64
25.8

30.06
22.89
33.99
21.8
24.9
23.06
29.03
35.2
30.36
31.8
25.32
22.51
19.32
21.37
23.14
37.87
27.58
24.15
32.47
23.2
24.05

CRL
CRL
CRL
CRL
CRL
CRL

UD
UD
UD
UD
UD
UD

29.27
28.65
28.27
33.7
32.81
31.22

28.61
25.9
24.56
33.82
29.43
29.58

NADC
PIADC
PIADC
PIADC
PIADC

UD
UD
UD
UD
UD

UD
UD
UD
UD
UD

UD
UD
UD
UD
UD

*CSFV = Classical swine fever virus; BDV = Border disease virus; BVDV = Bovine viral diarrhea virus; PIADC = Plum Island Animal Disease Center;
CRL = European Union Community Reference Laboratory; NADC = National Animal Disease Center; UD = undetected; NT = not tested.

Additional testing was conducted using a somewhat smaller
representative panel of 21 CSFV, 6 BDV, and 5 BVDV isolates, and pestivirus-negative samples resulted in similar
sensitivities of 99% between the tests; however, the resulting
specificities were 92% for the CSF PIADC assay and 68%
for the Risatti CSF assay (Table 2). This indicates that the
CSF PIADC assay is a more specific test and better suited as
a surveillance tool because of the risks and consequences
resulting from false-positive samples.
Sensitivities and LODs for the CSF PIADC and Risatti
CSF assays were determined and compared using dilutions

of RNA obtained from selected titered CSFV isolates. Only
results from the final optimized assays comparing the CSF
PIADC assay using ROX-supplemented Multiplex-NR
chemistry on the ABI 7900HT and ABI 7500 platforms as
compared to the Risatti CSF assay on the SmartCycler II
platform are shown (Table 3).
Performance of the CSF PIADC assay during diagnostic
sensitivity and specificity testing on nasal swab samples
from the Dominican Republic resulted in 59 positive and 93
negative reactions, while the Risatti CSF assay resulted in
the detection of 54 positive and 98 negative reactions. This
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Table 3. Development, optimization, and validation of a Classical swine fever virus (CSFV) real-time reverse transcription polymerase
chain reaction assay: analytical sensitivity presented as the limit of detection for diverse CSFV isolates using various assays and
platforms.*
Assay limit of detection
Risatti8 CSF

PIADC CSF
CSFV strain

Titer

ABI 7900HT†

ABI 7500 Fast†

SmartCycler II

Haiti
Brescia
Paderborn
Penjamo
Kanagawa
Guatemala
Percen
VD Bergen
Alfort

5
6.05
6.05
6.55
3.3
6.2
5.8
6.3
6.95

<1
<1
3.33
1.55
1.65
1.32
1.99
1.92
3.38

ND
<1
ND
ND
ND
1.73
<1
1.55
2.60

<1
<1
2.11
2.16
<1
ND
ND
ND
ND

*CSFV = Classical swine fever virus; PIADC = Plum Island Animal Disease Center; ND = not determined. Titer and LODs expressed as log10 TCID50/ml.
†Qiagen QuantiTect® Multiplex RT-PCR NoROX Kit supplemented with ROX.

indicates a greater sensitivity (100%) for the CSF PIADC
assay on diagnostic samples. The agreement in results comparing the CSF PIADC and Risatti CSF assays were evaluated with Cohen kappa statistic and estimated at κ = 0.93
(95% CI: 0.87, 0.99).
To further compare the CSF PIADC and Risatti CSF
assays, a total of 22 pigs were experimentally infected intranasally with 1 ml of CSFV Brescia (16 animals) or BDV (6 animals). Six uninfected pigs served as negative controls.
Animals were evaluated daily for clinical signs. Following
onset of clinical signs, animals were sampled by sterile nasal
swabsm that were then placed into 1.5-ml sterile tubes containing 1 ml of Dulbecco minimal essential medium containing
antibiotics and antimycotics.n Both assays detected CSFV
equally from all 16 pigs experimentally infected with CSFV;
however, the Risatti CSF assay also gave positive signals for
animals experimentally infected with BDV revealing a lower
specificity.
Overall, the CSF PIADC assay resulted in lower Ct values
as compared to the Risatti CSF assay, regardless of amplification platform. When comparing Ct values obtained for the
CSF PIADC assay on the ABI 7900HT to the Risatti CSF
assay on the SmartCycler II, there did not appear to be a
strong linear relationship or strong linear agreement between
the 2 platforms (Table 2). The 2 assays showed stronger linear relationship and linear agreement when both amplifications were conducted using the ABI 7900HT.
The estimated LODs ranged from <1 to 3.33 using the
CSF PIADC assay and from <1 to 2.16 using the Risatti CSF
assay (Table 3). Amplification efficiencies were 87% for the
PIADC CSF assay on the ABI 7900HT and 63% and 86% for
the Risatti CSF assay run on the SmartCycler II and ABI
7900HT, respectively.
Intra-assay variability was evaluated for the CSF PIADC
assay using the ABI 7900HT and the Risatti CSF assay using

the SmartCycler II and ABI 7900HT. Estimated intra-assay
variability for the PIADC CSF assay was 0.13 (95% CI: 0.10,
0.16) as compared with 1.00 (95% CI: 0.81, 1.30) and 0.16
(95% CI: 0.13, 0.21) for the Risatti CSF assay on the
SmartCycler II and ABI 7900HT, respectively. Results suggest similar well-to-well variability between the Risatti CSF
and the PIADC CSF when amplified on the ABI 7900 HT,
and also indicate greater tube-to-tube variation when the
Risatti CSF assay is amplified using the SmartCycler II.
With all PIADC CSF assay testing of culture isolates and
clinical material, the BDV, BVDV, and known negative samples resulted in negative reactions on both platforms and with
all chemistries evaluated. In tests conducted with diagnostic
samples using the ABI 7900HT, resulting Ct values were lowest using the Multiplex-NR kit followed by the SuperScript III
kit, and finally the Probe kit. In tests conducted with diagnostic samples using the ABI 7500, Ct values were lowest using
the SuperScript III as compared to the Multiplex-NR kit.
The cross-reactivity observed with the CSF Risatti assay
and BDV RNA is likely due in part to the high level of
sequence conservation shared among pestivirus 5′ untranslated regions, making specific primer and probe designs challenging.1 Indeed, in the original development and optimization
of the Risatti CSF assay,8 several BVDV (n = 6) and BDV
(n = 3) isolates were tested. While no fluorogenic signal was
detected using these near neighbor samples, no FAM threshold levels were indicated. Furthermore, agarose gel electrophoresis revealed BVDV- and BDV-specific PCR amplicons
of expected sizes indicating the potential for cross-reactive
forward and reverse primers but a lack of probe affinity for
BVDV and BDV in the Risatti CSF assay. In a follow-up
diagnostic evaluation of the Risatti CSF assay,7 sensitivity
and specificity were also evaluated. In this testing, sensitivity
was reported as 100% while specificity was reported as
89.9%. The specificity samples were negative nasal swabs
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(n = 384) and did not include known pestivirus near neighbors such as BVDV or BDV to challenge the assay.7
During a disease outbreak or in ongoing surveillance,
high-throughput capabilities will be necessary to handle the
high volumes of samples needing to be tested. The Risatti
CSF assay was originally developed and validated only for
single-tube extraction and amplification using a SmartCycler
system.8 In contrast, the CSF PIADC assay described herein
was developed to function on high-throughput 96-well platforms including the ABI 7900HT and ABI 7500 systems.
The greater specificity and versatility of the CSF PIADC
assay, having equivalency on different chemistries and
high-throughput 96-well diagnostic formats, will be a benefit to meeting the needs of a national surveillance program
or diagnostic surge in the event of a CSF outbreak.
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